The server is under maintenance between 08:00 to 12:00 (GMT+08:00), and please visit later.
We apologize for any inconvenience caused
Login  | Sign Up  |  Oriprobe Inc. Feed
China/Asia On Demand
Journal Articles
Laws/Policies/Regulations
Companies/Products
Bookmark and Share
a de fu wei zuo you hua zhi liao hbeag yin xing man xing yi xing gan yan liao xiao guan cha
Author(s): 
Pages: 237-239
Year: Issue:  3
Journal: World Phytomedicines

Keyword:  Adefovir dipivoxilLamivudinechronic hepatitis BHBeAg-negativeoptimal treatment;
Abstract: 目的优化阿德福韦酯抗乙肝病毒治疗策略,提高治疗效果。方法将42例HBeAg阴性慢性乙型肝炎患者依照HBV DNA载量分为2组,高病毒载量组22例,拉米夫定联合阿德福韦酯治疗;低病毒载量组20例,阿德福韦酯单药治疗,定期检测HBV DNA、肝功能和乙肝病毒血清标志物(HBV-M)。结果联合治疗组HBV DNA下降速度快,12周有效抑制率为72.7%,显著高于单药治疗组(x~2=23.49,P<0.001);治疗48周后两组患者均获得较高的病毒学应答,HBV DNA有效抑制率(95.45%vs 95%)和测不到率(77.27%vs 80.90%)无统计学差异(P>0.05);治疗12周及48周两组ALT复常率无差异(P>0.05),分别为40%、36.36%,90%、86.36%;两组患者均未出现严重不良反应。结论对于HBV DNA载量较低的初治HBeAg阴性慢性乙型肝炎患者,阿德福韦酯单药治疗可获得较好的疗效,而HBV DNA≥6 log拷贝/mL的高病毒载量患者则需要联合拉米夫定才能获得较高的病毒及生化学应答率。
Related Articles
No related articles found